Compare VIR & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | AVAH |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2019 | 2021 |
| Metric | VIR | AVAH |
|---|---|---|
| Price | $8.70 | $6.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $19.43 | $9.75 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.49 | ★ 1850.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | $68,556,000.00 | ★ $2,433,199,000.00 |
| Revenue This Year | $270.22 | $7.31 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | ★ N/A | $34.89 |
| Revenue Growth | N/A | ★ 20.19 |
| 52 Week Low | $4.16 | $3.73 |
| 52 Week High | $11.66 | $10.32 |
| Indicator | VIR | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 41.84 |
| Support Level | $8.48 | $6.18 |
| Resistance Level | $10.10 | $6.93 |
| Average True Range (ATR) | 0.42 | 0.37 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 8.63 | 9.94 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.